Ophthalmology

Clinical evidence, research, and medical intelligence in Ophthalmology.

MHRA issues Class 3 recall for Tropicamide 1% eye drops

MHRA announced a Class 3 recall for Aspire Pharma’s Tropicamide 1% eye drops in single-dose containers, affecting routine ophthalmic use.

A tool-augmented AI agent linked imaging data and guideline evidence in AMD follow-up, with 92% clinically appropriate decisions…

BOSU remains a unique national surveillance platform for rare eye conditions, enabling unbiased case ascertainment and population-based ophthalmic…

UK-funded AI eye scans may spot early diabetes and cardiovascular disease by reading retinal vessel changes during routine…

A Frontiers in Immunology review maps ocular fluid biomarkers and anti-retinal autoantibodies in neovascular AMD and proposes a…

Frontiers in Immunology corrected a uveitis single-cell paper to clarify re-analysis of prior samples and detail ocular and…

MHRA issued a Class 3 recall for specific Tropicamide 1% Eye Drops batches after incorrect expiry dates were…

A nationwide Korean cohort links hepatitis B and C infection with higher risks of exudative and nonexudative AMD…

A 2025 review examines retinal nanomedicine for drug delivery, theranostics, gene therapy, stem cells, optogenetics, and prostheses.

A large propensity-matched cohort study examined whether systemic hypoxia was associated with progression from NPDR to PDR and…

Ophthalmology

Clinical evidence, research, and medical intelligence in Ophthalmology.

In Brief The 5-minute rounds